Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | KDM1A | O60341 | 2/20 | 0.51 |
| ▸ | MAOA | P21397 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5127058 | 0.82 | GAA (0.64) | GAAMEN1KMT2ASMN1; SMN2CHRNA7 | |
| SCHEMBL3695388 | 0.81 | MEN1 (0.54) | GAAMEN1KMT2ASMN1; SMN2KDM1A | |
| SCHEMBL3695387 | 0.81 | MEN1 (0.54) | GAAMEN1KMT2ASMN1; SMN2KDM1A | |
| SCHEMBL5203595 | 0.80 | GAA (0.65) | GAAMEN1KMT2ASMN1; SMN2CHRNA7 | |
| SCHEMBL7955416 | 0.79 | GAA (0.64) | GAAMEN1KMT2AKDM1AMAOA | |
| SCHEMBL3932594 | 0.78 | GAA (0.70) | GAAMEN1KMT2ASMN1; SMN2KDM1A | |
| SCHEMBL6135838 | 0.77 | GAA (0.61) | GAAMEN1KMT2ASMN1; SMN2CHRNA7 | |
| SCHEMBL5802421 | 0.77 | GAA (0.61) | GAAMEN1KMT2ASMN1; SMN2CHRNA7 | |
| Hydrochloric Acid SCHEMBL30366367 | 0.75 | MEN1 (1.00) | GAAMEN1KMT2ASMN1; SMN2KDM1A | |
| Hydrochloric Acid SCHEMBL14119342 | 0.75 | MEN1 (1.00) | GAAMEN1KMT2ASMN1; SMN2KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1558610-B1 | SUBSTITUTED AMINOQUINUCLIDINE COMPOUNDS AND THEIR USE AS DELTA-OPIOID RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA NV (BE) | 2008-02-27 | — | — | EP | disclosed |
| US-7179818-B2 | Substituted aminoquinuclidine compounds | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-20040110789-A1 | Substituted aminoquinuclidine compounds | BOYD ROBERT E (US) | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110789-A1 | Substituted aminoquinuclidine compounds | OPRD1, OPRK1, OPRM1 | GAA 1636/4885MEN1 4876/4885KMT2A 1801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.